0

L-DOPS

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP23651958
CAS23651-95-8
Structure
MDL NumberMFCD00799030
Molecular Weight213.19
InChI KeyQXWYKJLNLSIPIN-JGVFFNPUSA-N
Description≥98% (HPLC)
SolubilityDMSO: ≥3 mg/mL
Assay≥98% (HPLC)
Colorwhite to tan
Formpowder
Size5MG, 25MG
Storage Conditions−20°C
1

Analgesic Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in Patients With Chronic Pain

H Takagi, A Harima

Eur Neuropsychopharmacol. 1996 Mar;6(1):43-7.

PMID: 8866937

1

Clinical Pharmacokinetics of the Norepinephrine Precursor L-threo-DOPS in Primary Chronic Autonomic Failure

David S Goldstein, Courtney Holmes, Horacio Kaufmann, Roy Freeman

Clin Auton Res. 2004 Dec;14(6):363-8.

PMID: 15666063

1

L-Dihydroxyphenylserine (L-DOPS): A Norepinephrine Prodrug

David S Goldstein

Cardiovasc Drug Rev. Fall-Winter 2006;24(3-4):189-203.

PMID: 17214596

1

L-threo-3,4-dihydroxyphenylserine (L-DOPS) Co-Administered With Entacapone Improves Freezing of Gait in Parkinson's Disease

Kei Fukada, Takuyuki Endo, Masaru Yokoe, Toshimitsu Hamasaki, Takanori Hazama, Saburo Sakoda

Med Hypotheses. 2013 Feb;80(2):209-12.

PMID: 23265352

1

The Noradrenaline Precursor L-DOPS Reduces Pathology in a Mouse Model of Alzheimer's Disease

Sergey Kalinin, Paul E Polak, Shao Xia Lin, Amul J Sakharkar, Subhash C Pandey, Douglas L Feinstein

Neurobiol Aging. 2012 Aug;33(8):1651-63.

PMID: 21705113

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode